9.264USD+7.89%Mkt Cap: —P/E: —1d ago
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleuce…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value83.42M $
Revenue (TTM)6.19M $
Gross Profit4.66M $
Net Income (TTM)-16.69M $
Revenue/Share0.4400 USD
Last Price9.264 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS0465131078
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.54
EV/Revenue13.47
P/S—
P/B-1.60
EPS (TTM)-3.65
EPS (Forward)—
52W Range
8.01063% of range10.00
52W High10.00 USD
52W Low8.010 USD
Profitability
Gross Margin75.27%
Oper. Margin-627.46%
EBITDA Margin-178.53%
Profit Margin-269.42%
ROE—
ROA-24.14%
Growth
Revenue Growth-96.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.89M $
CapEx (TTM)—
FCF Margin-202.17%
FCF Yield—
Net Debt6.00K $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity—
Current Ratio1.98
Quick Ratio1.49
Book Value/Sh-5.2570 USD
Cash/Share0.9840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.04:1
Split DateJun 20, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.45.65M
Float4.13M
Insiders15.19%
Institutions57.67%
Technical
SMA 500.7199 (+1186.9%)
SMA 2001.299 (+613.3%)
Beta0.10
S&P 52W Chg20.80%
Avg Vol (30d)1.39K
Avg Vol (10d)26.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—